Speaker: Prof. Marjolein van Egmond - Professor in Oncology and Inflammation, Amsterdam UMC
Speaker: Dr. Mark Claassen - Internist-infectiologist - Rijnstate Hepatitis Center Arnhem
Speaker: Prof. Marc Van Ranst - Director Clinical and Epidemiological Virology Unit Rega Institute for Medical Research - University of Leuven, Head of Laboratory Medicine - University Hospitals Leuven
Speaker: Prof. dr. ir. Alex Vorsters - University of Antwerp, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute
Speaker: Prof. dr. Eric van Gorp - Internist/infectiologist/virologist, Erasmus MC Rotterdam
Tremfya is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor.